Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Natecal Vitamine D3 is a fixed-dose combination medicinal product containing calcium carbonate and colecalciferol (Vitamin D3). Developed by Effik (a subsidiary of the Italfarmaco Group), it is indicated for the correction of combined vitamin D and calcium deficiencies, particularly in the elderly, and as a supplement to specific treatments for osteoporosis. Calcium is a vital mineral for bone mineralization and maintenance, while colecalciferol acts as a secosteroid hormone that enhances the intestinal absorption of calcium and phosphate and regulates their plasma concentrations. The product is typically formulated as orodispersible or chewable tablets to improve patient compliance and facilitate administration without water.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium carbonate + colecalciferol (Effik).